window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Neurodegenerative Diseases

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    AC Immune amends Lilly collaboration on Tau small molecules for Alzheimer’s disease

    AC Immune has amended its collaboration agreement with Eli Lilly [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Therapeutic Areas

    AstronauTx appoints Adam Rosenberg as Chair of the Board

    AstronauTx has appointed Adam Rosenberg as chair of the board, [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    AC Immune interim Phase 2 data suggest ACI-7104.056 may slow Parkinson’s disease progression

      AC Immune SA has reported positive interim results from [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    Medicinova wins contract research and development innovation award at biotech breakthrough awards 2025

    MediciNova has been recognised with the Contract Research and Development [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    TRIMTECH Therapeutics establishes scientific advisory board to advance targeted protein degradation

    TRIMTECH Therapeutics, a biotech developing small molecule therapeutics that selectively [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    NRG Therapeutics closes oversubscribed £50m series B to advance clinical data in Parkinson’s and proof of concept in ALS/MND

    NRG Therapeutics Ltd, a neuroscience company developing treatments targeting mitochondrial [...]

    May 5, 2026
  • Biotech & Pharma Business

    Alchemab Therapeutics signs $415m licensing deal with Lilly for ALS program

    May 5, 2026
  • Biotech & Pharma Business

    Roche to invest $50 billion in US pharmaceuticals and diagnostics over five years

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • FDA grants Fast Track status to SOTIO’s colorectal cancer ADC ahead of Phase 1/2 trial
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • EpilepsyGTx partners with ClearPoint Neuro to support Phase 1 gene therapy trial
    Categories: Advanced Therapies, Clinical & Regulatory, Drug Delivery & Formulation, Research & Development
  • Skyhawk expands global Huntington’s disease trial following positive Phase 1/2 data
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top